ARCHIVES

BMS Agent Yervoy Received FDA Approval for Metastatic Melanoma

This article is from The Cancer Letter archive.

Vol. 37 No. 12 | March 25, 2011

Download PDF Visit The Full Archive

Related Articles

Trials show No Advantage for ABMT In Breast Cancer; Should Insurers Pay?

April 16, 1999

Survey Shows That One-Third Of Patients Are Undertreated

April 27, 2012

Five-year Childhood ALL Survival Increased To 90.4 Percent by 2005

March 30, 2012

October issue of Business & Regulatory Report included.

November 5, 2004

NTP Committee Accepts Industry Positions On Policy To Separate Figures for Benign, Malignant Lesions

November 7, 1980

NIH review finds 44 scientists violated ethics rules on industry consulting, House committee chairman says.

July 15, 2005